Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis
WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) has completed patient enrollment in its Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis, marking a development milestone for …
Aclaris Completes Enrollment in Phase 2 Trial of Bosakitug for Atopic Dermatitis Read More